Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.

Authors

Lihua Elizabeth Budde

City of Hope National Medical Center, Duarte, CA

Lihua Elizabeth Budde , Theresa Deisher , Don A. Stevens , Gary J. Schiller , Stefano R. Tarantolo , Ryan C. Ramaekers , Peter Jarzyna , Spencer Sawas , Sandeep Mittal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.

First Author: John Ebben

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.

First Author: Thomas Lillie

insert_chart_outlined

Poster

2024 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Initial safety assessment of the endoscopically injected oncolytic virus OBP-301 in medically inoperable esophageal cancer: NRG-GI007.

First Author: Geoffrey Yuyat Ku

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.

First Author: Anwaar Saeed